# US 2021/0340529 A1 · Single-stranded rna-editing oligonucleotides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0340529 A1
- Document ID: US20210340529A1
- Status: Published application
- Kind: A1
- Application number: 17/214,087
- Filed: 2021-03-26
- Published: 2021-11-04
- Earliest claimed: 2016-06-22
- Assignees: ProQR Therapeutics II B.V.
- Applicants: ProQR Therapeutics II B.V.
- Inventors: Janne Juha Turunen; Petra Geziena De Bruijn; Bart Klein; Roxana Simona Redis; Lenka Van Sint Fiet
- Web page: https://patentgrep.com/patent/US20210340529A1

## CPC

- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- A61K 31/7125: Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 7/06: Antianaemics
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 11/08: Bronchodilators
- A61P 17/00: Drugs for dermatological disorders
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 2310/11: Antisense
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/3521: Methyl
- C12N 2310/3527: Other alkyl chain
- C12N 2320/30: Special therapeutic applications
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to antisense oligonucleotides that are capable of bringing about specific editing of a target nucleotide (adenosine) in a target RNA in a eukaryotic cell, wherein said oligonucleotide does not, in itself, form an intramolecular hairpin or stem-loop structure, and wherein said oligonucleotide comprises a cytidine non-complementary, nucleotide) or a uridine in a position opposite to the target adenosine to be edited in the target RNA region.

## Claims

### Claim at position 1

-19. (canceled)

### Claim 20

An antisense oligonucleotide (AON) capable of forming a double stranded complex with a target RNA in a cell for the deamination of a target adenosine present in the target RNA by an ADAR enzyme present in the cell, wherein:
(a) the AON is complementary to a target RNA region comprising the target adenosine, and the AON comprises one or more mismatches, wobbles and/or bulges with the complementary target RNA region;
(b) the AON comprises one or more nucleotides with one or more sugar modifications, provided that the nucleotide opposite the target adenosine comprises a ribose with a 2′-OH group, or a deoxyribose with a 2′-H group;
(c) the AON does not comprise a portion that is capable of forming an intramolecular stem-loop structure capable of binding an ADAR enzyme;
(d) the AON does not include a 5′-terminal O6-benzylguanine modification;
(e) the AON does not include a 5′-terminal amino modification; and
(f) the AON is not covalently linked to a SNAP-tag domain.

### Claim 21

An AON capable of forming a double stranded complex with a target RNA in a cell for the deamination of a target adenosine present in the target RNA by an ADAR enzyme present in the cell, wherein:
(a) the AON is complementary to a target RNA region comprising the target adenosine, and the AON comprises one or more mismatches, wobbles and/or bulges with the complementary target RNA region;
(b) the AON comprises one or more nucleotides with one or more sugar modifications, provided that the nucleotide opposite the target adenosine comprises a ribose with a 2′-OH group, or a deoxyribose with a 2′-H group;
(c) the AON does not comprise a portion that is capable of forming an intramolecular stem-loop structure capable of binding an ADAR enzyme; and
(d) the AON is not a 17-mer or a 20-mer.

### Claim 22

An AON capable of forming a double stranded complex with a target RNA in a cell for the deamination of a target adenosine present in the target RNA by an ADAR enzyme present in the cell, wherein:
(a) the AON is complementary to a target RNA region comprising the target adenosine, and the AON comprises one or more mismatches, wobbles and/or bulges with the complementary target RNA region;
(b) the AON comprises one or more nucleotides with one or more sugar modifications, provided that the nucleotide opposite the target adenosine comprises a ribose with a 2′-OH group, or a deoxyribose with a 2′-H group;
(c) the AON does not comprise a portion that is capable of forming an intramolecular stem-loop structure capable of binding an ADAR enzyme; and
(d) the AON is longer than 17 nucleotides, or shorter than 14 nucleotides.

### Claim 23

An AON capable of forming a double stranded complex with a target RNA in a cell for the deamination of a target adenosine present in the target RNA by an ADAR enzyme present in the cell, wherein:
(a) the AON is complementary to a target RNA region comprising the target adenosine;
(b) the AON comprises one or more nucleotides with one or more sugar modifications, provided that the nucleotide opposite the target adenosine comprises a ribose with a 2′-OH group, or a deoxyribose with a 2′-H group;
(c) the AON does not comprise a portion that is capable of forming an intramolecular stem-loop structure that is capable of binding an ADAR enzyme;
(d) the AON comprises 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 mismatches, wobbles and/or bulges with the complementary target RNA region.

### Claim 24 (depends on 20)

The AON of claim 20, wherein the nucleotide opposite the target adenosine is a cytidine, a deoxycytidine, a uridine, or a deoxyuridine.

### Claim 25 (depends on 20)

The AON of claim 20, wherein the nucleotide directly 5′ and/or 3′ from the nucleotide opposite the target adenosine comprises a ribose with a 2′-OH group, or a deoxyribose with a 2′-H group.

### Claim 26 (depends on 25)

The AON of claim 25, wherein all other nucleotides in the AON comprise a 2′-O-alkyl group.

### Claim 27 (depends on 20)

The AON of claim 20, comprising at least one phosphorothioate linkage.

### Claim 28 (depends on 27)

The AON of claim 27, wherein the 2, 3, 4, 5, or 6 terminal nucleotides of the 5′ and 3′ terminus of the AON are linked with a phosphorothioate linkage.

### Claim 29 (depends on 28)

The AON of claim 28, wherein the 5 terminal nucleotides of the 5′ and 3′ terminus of the AON are linked with phosphorothioate linkages.

### Claim 30 (depends on 20)

The AON of claim 20, wherein the AON is longer than 10, 11, 12, 13, 14, 15, 16 or 17 nucleotides.

### Claim 31 (depends on 20)

The AON of claim 20, wherein the AON is shorter than 100 nucleotides.

### Claim 32 (depends on 20)

The AON of claim 20, wherein the AON comprises 18 to 70 nucleotides.

### Claim 33 (depends on 20)

A pharmaceutical composition comprising the AON of claim 20 and a pharmaceutically acceptable carrier.

### Claim 34 (depends on 20)

A method of treating or preventing a genetic disorder in a subject in need thereof, the method comprising administering the AON of claim 20 to the subject.

### Claim 35 (depends on 20)

A method of deaminating at least one target adenosine present in a target RNA in a cell, the method comprising:
(i) contacting a cell with the AON of claim 20 thereby to permit the AON to enter the cell and an ADAR enzyme comprising a natural dsRNA binding domain to deaminate the target adenosine in the target RNA to an inosine; and
(ii) optionally identifying the presence of the inosine in the targeted RNA.

### Claim 36 (depends on 35)

The method of claim 35, wherein step (ii) comprises:
(a) sequencing the targeted RNA sequence;
(b) assessing the presence of a functional, elongated, full length and/or wild type protein when the target adenosine is located in a UGA or UAG stop codon, which is edited to a UGG codon through the deamination;
(c) assessing the presence of a functional, elongated, full length and/or wild type protein when two target adenosines are located in a UAA stop codon, which is edited to a UGG codon through the deamination of both target adenosines;
(d) assessing whether splicing of the pre-mRNA was altered by the deamination; or
(e) using a functional read-out, wherein the target RNA after the deamination encodes a functional, full length, elongated and/or wild type protein.

### Claim 37 (depends on 20)

The AON of claim 20, wherein the target RNA sequence encodes CFTR, CEP290, alpha1-antitrypsin (A1AT), LRRK2, BDNF, or wherein the target RNA is encoded by the IDUA gene.

### Claim 38 (depends on 26)

The AON of claim 26, wherein all other nucleotides in the AON comprise a 2′-O-methyl group.

### Claim 39 (depends on 34)

The method of claim 34, wherein the genetic disorder is selected from the group consisting of: Cystic fibrosis, Hurler Syndrome, alpha-1-antitrypsin (A1AT) deficiency, Parkinson's disease, Alzheimer's disease, albinism, Amyotrophic lateral sclerosis, Asthma, β-thalassemia, Cadasil syndrome, Charcot-Marie-Tooth disease, Chronic Obstructive Pulmonary Disease (COPD), Distal Spinal Muscular Atrophy (DSMA), Duchenne/Becker muscular dystrophy, Dystrophic Epidermolysis bullosa, Epidermylosis bullosa, Fabry disease, Factor V Leiden associated disorders, Familial Adenomatous, Polyposis, Galactosemia, Gaucher's Disease, Glucose-6-phosphate dehydrogenase, Haemophilia, Hereditary Hematochromatosis, Hunter Syndrome, Huntington's disease, Inflammatory Bowel Disease (IBD), Inherited polyagglutination syndrome, Leber congenital amaurosis, Lesch-Nyhan syndrome, Lynch syndrome, Marfan syndrome, Mucopolysaccharidosis, Muscular Dystrophy, Myotonic dystrophy types I and II, neurofibromatosis, Niemann-Pick disease type A, B and C, NY-esol related cancer, Peutz-Jeghers Syndrome, Phenylketonuria, Pompe's disease, Primary Ciliary Disease, Prothrombin mutation related disorders, such as the Prothrombin G20210A mutation, Pulmonary Hypertension, Retinitis Pigmentosa, Sandhoff Disease, Severe Combined Immune Deficiency Syndrome (SCID), Sickle Cell Anemia, Spinal Muscular Atrophy, Stargardt's Disease, Tay-Sachs Disease, Usher syndrome, X-linked immunodeficiency, and cancer.
